NIH taps four regional groups to share $5.5M in initial Precision Medicine Initiative funding

The National Institutes of Health has tapped four regional medical center groups to share $5.5 million in funding as part of President Barack Obama’s Precision Medicine Initiative program.

The program is designed to support research efforts that target more than 1 million U.S. participants to help improve methods of preventing and treating disease based on individual differences in lifestyle, environment and genetics.

The funding for the four healthcare provider organizations is for efforts to begin initial enrollment of participants as well as collecting their health information and biospecimens, and to provide input on developing plans for the program.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The recipients are:

  • California Precision Medicine Consortium: University of California, San Diego; with partners Cedars-Sinai Medical Center, Los Angeles; San Diego Blood Bank; University of California, Davis; University of California Health; University of California, Irvine; University of California, San Francisco; and University of Southern California, Los Angeles
  • Geisinger Health System, Danville, PA
  • New England Precision Medicine Consortium: Partners HealthCare System and its hospitals, Massachusetts General Hospital and Brigham and Women’s Hospital, with Boston University and Boston Medical Center
  • Trans-American Consortium for the Health Care Systems Research Network: Henry Ford Health System, Detroit, MI, with partners Baylor Scott and White Research Institute, Dallas, TX; Essentia Health, Duluth, MN; Spectrum Health, Grand Rapids, MI; and University of Massachusetts Medical School, Worcester, MA.

“These additional health care provider organizations will help us in our efforts to reach communities that have been underrepresented in research,” Eric Dishman, director of the PMI Cohort Program, said in a statement. “By contributing their information, these communities will help people and their health care providers identify the right prevention strategies or treatments.”

Researchers will maximize results by tracking participants' individual genetic characteristics. They will also look at how environment can impact genetic predispositions to disease.

Suggested Articles

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.